[1] Wanka, L., Iqbalb, K. and Schreiner, P.R. (2013) The Lipophilic Bullet Hits the Targets: Medicinal Chemistry of Adamantane Derivatives. Chemical Reviews, 113, 3516-3604.
http://dx.doi.org/10.1021/cr100264t
[2] Crosby, N.J., Deane, K. and Clarke, C.E. (2003) Amantadine for Dyskinesia in Parkinson’s Ddisease. Cochrane Database of Systematic Reviews, 2, CD003467.
[3] Sawada, H., Oeda, T., Kuno, S., Nomoto, M., Yamamoto, K., Yamamoto, M., Hisanaga, K., Kawamura, T., and for the Amantadine Study Group (2010) Amantadine for Dyskinesias in Parkinson’s Disease: A Randomized Controlled Trial. PLoS ONE, 12, e15298.
http://dx.doi.org/10.1371/journal.pone.0015298
[4] Schwab, R.S., England, A.C., Poskanzer, D.C. and Young, R.R. (1969) Amantadine in the Treatment of Parkinson’s Disease. JAMA, 208, 1168-1170. http://dx.doi.org/10.1001/jama.1969.03160070046011
[5] Reisberg, B., Doody, R., St?ffler, A., Schmitt, F., Ferris, S., M?bius, H.J., and for the Memantine Study Group (2003) Memantine in Moderate-to-Severe Alzheimer’s Disease. The New England Journal of Medicine, 14, 1333-1341.